Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Open accessThe DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Abstract
: 1. After 50 years of antipsychotic drug development focused on the dopamine D2 receptor, schizophrenia remains a chronic, disabling disorder for most affected individuals. 2. Studies over the last decade demonstrate that administration of low doses of NMDA receptor antagonists can cause in normal subjects the negative symptoms, cognitive impairments and physiologic disturbances observed in schizophrenia. 3. Furthermore, a number of recently identified risk genes for schizophrenia affect NMDA receptor function or glutamatergic neurotransmission. 4. Placebo-controlled trials with agents that directly or indirectly activate the glycine modulatory site on the NMDA receptor have shown reduction in negative symptoms, improvement in cognition and in some cases reduction in positive symptoms in schizophrenic patients receiving concurrent antipsychotic medications. 5. Thus, hypofunction of the NMDA receptor, possibly on critical GABAergic inter-neurons, may contribute to the pathophysiology of schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prefrontal cortex (PFC) and hippocampus stand out as major regions affected in schizophrenia”
From Adolescent Onset of Cortical Disinhibition in Schizophrenia: Insights From Animal Models (2011) · cites this paper as [3]
In the citing paper
“A loss of scaffolding proteins in spines could alter glutamatergic receptor signaling, disruption of which is theorized to contribute to the etiology of schizophrenia60.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [60]
In the citing paper
“Overactivity of NMDA receptors causing excitotoxicity is a proposed underlying mechanism for epilepsy, dementia, and stroke, whereas low activity produces symptoms of schizophrenia.2–4”
From Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies (2008) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · cited 1×
“Existing drugs are poorly tolerated and exhibit little differences in efficacy (Lieberman et al., 2005).”
BackgroundKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 2×
“Newcomer et al. (1999) extended the findings of Krystal et al. (1994) by showing that declarative memory, the form impaired in schizophrenia, was quite sensitive to low dose ketamine infusion.”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Based upon the emerging pharmacology of the NMDAR, Javitt and Zukin (1991) proposed that the psychotomimetic effects of PCP were due to blockade of the NMDA receptors.”
BackgroundTripartite synapses: glia, the unacknowledged partner
Araque, A., Parpura, V., Sanzgiri, R. P., & Haydon, P. G. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01349-6 · Cited by 2,529 · cited 1×
“The glutamatergic synapse consists of a tight functional relationship among the presynaptic terminal, the postsynaptic spine and the ensheathing astrocyte end-foot (Araque et al., 1999; Coyle et al., 2002).”
BackgroundSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergence
Harrison, P. J., & Weinberger, D. R. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001558 · Cited by 2,020
The hippocampal-VTA loop: controlling the entry of information into long-term memory
Lisman, J. E., & Grace, A. A. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.002 · Cited by 1,983
Braff, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,705
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 2×
“In addition, clozapine treatment has been associated with reduction in the rate of suicide, reduction in smoking and reduction in abuse of other substances in schizophrenic patients (Drake et al., 2000; Meltzer et al., 2003; Zimmet et al., 2000).”
BackgroundLesion of striatal neurons with kainic acid provides a model for Huntington's chorea
COYLE, J. T., & SCHWARCZ, R. (1976) · Nature · doi:10.1038/263244a0 · Cited by 1,248 · cited 1×
“We focused on glutamatergic signal transduction before there was any evidence that it could be relevant to neuropsychiatric disorders (Coyle and Schwarcz, 1976).”
BackgroundSelf-citation
Research works printed but not linked: 1
- Wang, X., He, G., Gu, N., Yang, J., Tang, J., Chen, Q., et al. (2004). Association of G72/G30 with schizophrenia in the Chinese population. Biochem. Biophys. Res. Commun. 319:1281–1286. · DOI
Cited by
Items 101–200 of 954
Bakker, P. R., van Harten, P. N., & van Os, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002142 · Cited by 154
Marx, C. E., Bradford, D. W., Hamer, R. M., Naylor, J. C., Allen, T. B., Lieberman, J. A., Strauss, J. L., & Kilts, J. D. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.076 · Cited by 160
Labrie, V., Lipina, T. V., & Roder, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1196-6 · Cited by 143
“Indeed, several clinical studies have shown symptomatic improvements with drugs that directly and indirectly activate NMDAR, including D-serine, which is a highly selective and potent agonist for the NMDA-NR1 glycine site (Coyle 2006; Matsui et al. 1995; Millan 2005; Tsai et al. 1998).”
BackgroundGroves, N. J., Kesby, J. P., Eyles, D. W., McGrath, J. J., Mackay‐Sim, A., & Burne, T. H. J. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.12.001 · Cited by 148
“This dysfunction may be related more to the negative and cognitive symptoms of schizophrenia [53].”
BackgroundWang, Q., Charych, E. I., Pulito, V. L., Lee, J. B., Graziane, N. M., Crozier, R. A., Revilla-Sanchez, R., Kelly, M. P., Dunlop, A. J., Murdoch, H., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.87 · Cited by 141
Early Sensory Contributions to Contextual Encoding Deficits in Schizophrenia
Dias, E. C., Butler, P. D., Hoptman, M. J., & Javitt, D. C. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.17 · Cited by 139
Pei, Y., Asif-Malik, A., & Canales, J. J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00148 · Cited by 159
“Apart from dysfunctional dopaminergic activity, reduced glutamatergic transmission has also been proposed as a causal factor in schizophrenia, particularly in relation to the negative symptoms and cognitive impairment associated with the disease (Javitt, 2004; Coyle, 2006; Goff and Coyle, 2014).”
BackgroundTanda, K., Nishi, A., Matsuo, N., Nakanishi, K., Yamasaki, N., Sugimoto, T., Toyama, K., Takao, K., & Miyakawa, T. (2009) · Molecular Brain · doi:10.1186/1756-6606-2-19 · Cited by 134
“The interaction between glutamatergic and dopaminergic pathways is crucial for cognitive and motor functions, and both signal transduction pathways are major contributing factors in schizophrenia pathogenesis [35].”
BackgroundMartins-de-Souza, D., Harris, L. W., Guest, P. C., & Bahn, S. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3459 · Cited by 134
“In general, it appears to be characterized by synaptic deficits, particularly in the dorso-lateral prefrontal cortex (DLPFC) and hippocampus (35), alterations in glutamate and dopamine neurotransmission (15, 43), and hypofrontality (87).”
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
Maksymetz, J., Moran, S. P., & Conn, P. J. (2017) · Molecular Brain · doi:10.1186/s13041-017-0293-z · Cited by 146
“While most current antipsychotics act by antagonizing the hyperdopaminergic and hyperserotonergic states underlying the positive symptoms, there is a growing body of evidence that supports glutamate dysfunction as a contributing factor for the disease [9, 10].”
BackgroundTuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex
Castner, S. A., & Williams, G. V. (2007) · Brain and Cognition · doi:10.1016/j.bandc.2006.11.002 · Cited by 144
G protein-coupled receptors in major psychiatric disorders
Catapano, L. A., & Manji, H. K. (2006) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.025 · Cited by 145
Rees, E., Walters, J. T. R., Chambert, K. D., O'Dushlaine, C., Szatkiewicz, J., Richards, A. L., Georgieva, L., Mahoney-Davies, G., Legge, S. E., Moran, J. L., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddt540 · Cited by 128
“Glutamate acts on NMDAR receptors, and a large body of evidence has associated NMDAR dysfunction with schizophrenia (30).”
BackgroundInhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting
Zang, Y. (2009) · Frontiers in Neural Circuits · doi:10.3389/neuro.04.020.2009 · Cited by 127
“NMDAR hypofunction is likely to have multiple origins (Coyle, 2006; Allen et al., 2008).”
Gray, L., van den Buuse, M., Scarr, E., Dean, B., & Hannan, A. J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009085 · Cited by 130
“Disturbances in glutamatergic signalling are now central to many models of schizophrenia aetiology (Coyle, 2006; Konradi andHeckers, 2003 ; Krystal et al., 2003 ; Moghaddam, 2003; Tamminga, 1998).”
BackgroundThe possible role of the Akt signaling pathway in schizophrenia
Zheng, W., Wang, H., Zeng, Z., Lin, J., Little, P. J., Srivastava, L. K., & Quirion, R. (2012) · Brain Research · doi:10.1016/j.brainres.2012.06.032 · Cited by 141
Human D-Amino Acid Oxidase: Structure, Function, and Regulation
Pollegioni, L., Sacchi, S., & Murtas, G. (2018) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2018.00107 · Cited by 131
“An NMDAR hypofunction was also related to schizophrenia (Coyle et al., 2003; Coyle, 2006; Stone and Pilowsky, 2007): the altered activation state of the receptor was proposed to depend on a deficiency in D-serine signaling (Hashimoto et al.”
BackgroundLiu, Y., Ouyang, P., Zheng, Y., Mi, L., Zhao, J., Ning, Y., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664535 · Cited by 129
“Similarly, alterations in cortico-striatal connections as well as functional connectivity between the thalamus and frontal/sensory support the hypothesis of neural disinhibition in schizophrenia (Coyle, 2006).”
BackgroundNikulin, V. V., Jönsson, E. G., & Brismar, T. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.03.008 · Cited by 137
“Due to the fact that in general schizophrenia is associated with drastically affected glutamatergic (Coyle, 2006) and GABAergic activities (Hashimoto et al., 2008), NeuroImage 61 (2012) 162–169 ⁎ Corresponding author at: Department of Neurology, Charité-University Medicine Berlin, D-12200 Berlin,…”
BackgroundInfluentialPotential Impact of miR-137 and Its Targets in Schizophrenia
Wright, C., Turner, J. A., Calhoun, V. D., & Perrone-Bizzozero, N. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00058 · Cited by 120
“The potential role of miR137 in the expression of these glutamate receptors could explain not only the altered glutamate signaling observed in schizophrenia (Coyle, 2006; Sendt et al., 2012), but also the LTP disruption in the illness, which may in turn contribute to the associated cognitive deficits.”
BackgroundTodd, J., Michie, P. T., Schall, U., Ward, P. B., & Catts, S. V. (2011) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2011.10.003 · Cited by 139
“Glutamate hypofunction plays a central role in the neurochemistry of schizophrenia (Coyle, 2006).”
BackgroundInfluentialHoriguchi, M., Huang, M., & Meltzer, H. Y. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180638 · Cited by 130
“These results suggest 5-HT7 antagonism may contribute to the efficacy of some atypical APDs in the treatment of cognitive impairment in schizophrenia and may itself have some benefit in this regard.”
The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment
Meltzer, H. Y., Horiguchi, M., & Massey, B. W. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2137-8 · Cited by 134
“regard to the etiology and pathophysiology of schizophrenia (Meltzer and Stahl 1976; Davis et al. 1991; Kapur et al. 2005; Javitt and Zukin 1991; Coyle 2006).”
BackgroundLisman, J. E., Pi, H. J., Zhang, Y., & Otmakhova, N. A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.007 · Cited by 115
Astrocyte‐derived kynurenic acid modulates basal and evoked cortical acetylcholine release
Zmarowski, A., Wu, H. ‐., Brooks, J. M., Potter, M. C., Pellicciari, R., Schwarcz, R., & Bruno, J. P. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06594.x · Cited by 122
“…neurotransmitter systems, including dopamine (Laruelle et al., 2003; Toda & Abi-Dargham, 2007), glutamate (Krystal et al., 2003; Moghaddam, 2003; Coyle, 2006), c-aminobutyric acid (GABA) (Lewis & Moghaddam, 2006), and acetylcholine (ACh) (Hyde & Crook, 2001; Sarter et al., 2005), throughout a…”
BackgroundInfluentialMitochondrial dysfunction in schizophrenia: With a focus on postmortem studies
Roberts, R. C. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.11.009 · Cited by 126
“Evidence from in vivo imaging, postmortem studies and animal models of schizophrenia implicate the glutamatergic system in schizophrenia as well (Coyle, 2006; Goff and Coyle, 2001; Javitt, 2004; Krystal, 2008), particularly in treatment resistant schizophrenia (Demjaha et al., 2014).”
BackgroundLabrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 129
“Though D-serine and similar compounds have demonstrated promising effects in clinical trials with medicated schizophrenia patients (Heresco-Levy et al., 2005; Tsai et al., 1998; Coyle, 2006), there are issues regarding the administration of these compounds, as large doses are required for therapeutic effect.”
BackgroundInfluentialToxoplasma gondii and Schizophrenia: Linkage Through Astrocyte-Derived Kynurenic Acid?
Schwarcz, R., & Hunter, C. A. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm030 · Cited by 116
Impaired long-term depression in schizophrenia: A cathodal tDCS pilot study
Hasan, A., Nitsche, M. A., Herrmann, M., Schneider-Axmann, T., Marshall, L., Gruber, O., Falkai, P., & Wobrock, T. (2012) · Brain Stimulation · doi:10.1016/j.brs.2011.08.004 · Cited by 110
Faure, A., Richard, J. M., & Berridge, K. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011223 · Cited by 114
“Likewise, in caudal shell, GABA and glutamate signals may normally function to adaptively make threat-related stimuli frightening in appropriate situations, but at excessively higher levels contribute to levels of pathological paranoia in schizophrenia and related disorders [61,62,63,64,65,66].”
BackgroundSerine racemase deletion disrupts memory for order and alters cortical dendritic morphology
DeVito, L. M., Balu, D. T., Kanter, B. R., Lykken, C., Basu, A. C., Coyle, J. T., & Eichenbaum, H. (2011) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00656.x · Cited by 114
“…NMDAR function is important for specific aspects of cognition, as well as the dendritic characteristics of cortical pyramidal neurons, and suggest that NMDAR hypofunction might, in part, be contributing to the cognitive and synaptic changes observed in schizophrenia (Coyle 1996, 2006; Javitt 2006).”
BackgroundSelf-citationCholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases
Petrov, A. M., & Pikuleva, I. A. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00731-6 · Cited by 118
BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders
Schubert, C. R., O’Donnell, P., Quan, J., Wendland, J. R., Xi, H. S., Winslow, A. R., Domenici, E., Essioux, L., Kam-Thong, T., Airey, D. C., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.047 · Cited by 123
Dendritic Spine Elimination: Molecular Mechanisms and Implications
Stein, I. S., & Zito, K. (2018) · The Neuroscientist · doi:10.1177/1073858418769644 · Cited by 122
Kokkinou, M., Irvine, E. E., Bonsall, D. R., Natesan, S., Wells, L. A., Smith, M., Glegola, J. A., Paul, E. J., Tossell, K., Veronese, M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0740-6 · Cited by 116
Kempf, L., Nicodemus, K. K., Kolachana, B., Vakkalanka, R., Verchinski, B. A., Egan, M. F., Straub, R. E., Mattay, V. A., Callicott, J. H., Weinberger, D. R., et al. (2008) · PLoS Genetics · doi:10.1371/journal.pgen.1000252 · Cited by 108
“Dysfunction in glutamatergic neurotransmission has been widely implicated in the pathophysiology of schizophrenia [46].”
BackgroundParellada, E., & Gassó, P. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01385-9 · Cited by 100
Mouse models of genetic effects on cognition: Relevance to schizophrenia
Papaleo, F., Lipska, B. K., & Weinberger, D. R. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.025 · Cited by 111
Lyon, L., Saksida, L., & Bussey, T. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2536-5 · Cited by 117
Dedic, N., Dworak, H., Zeni, C. M., Rutigliano, G., & Howes, O. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413185 · Cited by 106
Girgis, R. R., Javitch, J. A., & Lieberman, J. A. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.40 · Cited by 113
Chang, L., Friedman, J. I., Ernst, T., Zhong, K., Tsopelas, N. D., & Davis, K. L. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.025 · Cited by 114
“Furthermore, recent data suggest dysfunctional interactions between the glutamatergic and dopaminergic systems may ultimately lead to excess release of glutamate (7,8), in particular in schizophrenic patients with cognitive impairment and negative symptoms (9).”
BackgroundBalu, D. T., Basu, A. C., Corradi, J. P., Cacace, A. M., & Coyle, J. T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.006 · Cited by 98
“Over the past two decades, there has been converging evidence supporting the hypothesis that N-methyl-D-aspartate receptor (NMDAR) hypofunction is a key component in the etiology of schizophrenia (Coyle, 2006; Javitt and Zukin, 1991; Krystal et al., 1994; Tsai et al., 1995).”
InfluentialSelf-citationDoes the dopamine hypothesis explain schizophrenia?
Lau, C. I., Wang, H.-C., Hsu, J.-L., & Liu, M. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0011 · Cited by 133
D-Amino Acid Oxidase Inhibitors as a Novel Class of Drugs for Schizophrenia Therapy
Sacchi, S., Rosini, E., Pollegioni, L., & Molla, G. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319140002 · Cited by 104
“Genetic studies have identified several risk genes for schizophrenia that influence NMDAR activity [10, 13].”
BackgroundInfluentialKarlsson, R., Tanaka, K., Heilig, M. A., & Holmes, A. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.001 · Cited by 106
Ohide, H., Miyoshi, Y., Maruyama, R., Hamase, K., & Konno, R. (2011) · Journal of Chromatography B · doi:10.1016/j.jchromb.2011.06.028 · Cited by 99
Pathmanandavel, K., Starling, J., Merheb, V., Ramanathan, S., Sinmaz, N., Dale, R. C., & Brilot, F. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.07.014 · Cited by 106
Dauvermann, M. R., Lee, G. L., & Dawson, N. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13919 · Cited by 102
“…hypofunction model’ postulates that prolonged hypoactivation of theNMDA receptor induces multiple pathological mechanisms involved in the disorder (Coyle, 2006; Coyle et al., 2010; Moghaddam and Krystal, 2012; Javitt et al., 2012) and that NMDA receptor hypofunction may be the final…”
BackgroundInfluentialTargeting glutamate synapses in schizophrenia
Field, J. R., Walker, A. G., & Conn, P. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.004 · Cited by 105
NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms
Snyder, M. A., & Gao, W. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.03.010 · Cited by 101
“…induce the onset of cognitive dysfunction, NMDAR hypofunction appears to be a convergence point for progression and symptoms of SZ, especially for cognitive deficits (Cohen et al., 2015; Coyle, 2006; Lisman et al., 2008; Marek, 2010; Moghaddam, 2003; Nakazawa et al., 2017; Snyder and Gao, 2013).”
BackgroundAmoah, S. K., Rodriguez, B. A., Logothetis, C., Chander, P. N., Sellgren, C. M., Weick, J. P., Sheridan, S. D., Jantzie, L. L., Webster, M. J., & Mellios, N. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0579-1 · Cited by 98
Structure–function relationships in human d-amino acid oxidase
Sacchi, S., Caldinelli, L., Cappelletti, P., Pollegioni, L., & Molla, G. (2012) · Amino Acids · doi:10.1007/s00726-012-1345-4 · Cited by 97
Konradsson-Geuken, Å., Wu, H. Q., Gash, C. R., Alexander, K. S., Campbell, A., Sozeri, Y., Pellicciari, R., Schwarcz, R., & Bruno, J. P. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.05.052 · Cited by 93
Mismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals
Näätänen, R., Todd, J., & Schall, U. (2015) · Biological Psychology · doi:10.1016/j.biopsycho.2015.10.010 · Cited by 98
Barkus, C., Sanderson, D. J., Rawlins, J. N. P., Walton, M. E., Harrison, P. J., & Bannerman, D. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.91 · Cited by 101
Duan, A. R., Varela, C., Zhang, Y., Shen, Y., Xiong, L. L., Wilson, M. A., & Lisman, J. E. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.01.020 · Cited by 101
Roalf, D. R., Nanga, R. P. R., Rupert, P. E., Hariharan, H., Quarmley, M., Calkins, M. E., Dress, E. M., Prabhakaran, K., Elliott, M. A., Moberg, P. J., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.258 · Cited by 95
Liu, C., Zhu, J., Zheng, X., Ma, C., & Wang, X. (2017) · Mediators of Inflammation · doi:10.1155/2017/6361479 · Cited by 100
“Excitotoxicity caused by the overactivity of NMDA receptors may lead to such disorders as stroke, epilepsy, Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease [19], while low activity of NMDA receptors may result in schizophrenia [20].”
BackgroundLitman, R. E., Smith, M. A., Doherty, J., Cross, A. J., Raines, S. R., Gertsik, L., & Zukin, S. R. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.001 · Cited by 93
“Abnormal glutamatergic neurotransmission has been proposed as an important component of schizophrenia pathophysiology (Coyle, 2006; Lin et al., 2012; Javitt and Zukin, 1991).”
TMS-EEG: An emerging tool to study the neurophysiologic biomarkers of psychiatric disorders
Cao, K.-X., Ma, M.-L., Wang, C.-Z., Iqbal, J., Si, J., Xue, Y.-X., & Yang, J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108574 · Cited by 96
Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications
Pikuleva, I. A., & Cartier, N. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.696778 · Cited by 80
“Conversely, CYP46A1 inhibition could be of therapeutic value in pathological conditions that promote excessive glutamatergic excitation such as those occurring in schizophrenia, epilepsy, and hyperalgesia (Coyle, 2006; Xia et al., 2010; Sun et al., 2016b; Lu et al., 2020).”
BackgroundHalff, E. F., Rutigliano, G., Garcia-Hidalgo, A., & Howes, O. D. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.10.010 · Cited by 96
“NMDAR dysfunction may particularly impact on inhibitory GABA interneurons, leading to disinhibition of glutamatergic pyramidal neurons [86].”
BackgroundEffect of cannabidiol in a MK-801-rodent model of aspects of Schizophrenia
Gururajan, A., TAYLOR, D. A. H. B., & Malone, D. T. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.053 · Cited by 91
“Neuropharmacological profile of a novel potential atypical antipsychotic drug Y-931 (8-fluoro-12-(4-methylpiperazin-1-yl)- 6H[1]benzothieno[2,3-b][1,5]benzodiazepinemaleate).”
BackgroundFell, M. J., McKinzie, D. L., Monn, J. A., & Svensson, K. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.007 · Cited by 97
“…antagonism or hypofunction may led to complex, but relatively selective dysfunction of limbic circuits involving both glutamatergic and GABAergic neurotransmission, which leads to downstream increases in glutamate release (see Coyle, 2006; Lisman et al., 2008; Marino and Conn, 2002 for reviews).”
BackgroundAn attractor hypothesis of obsessive–compulsive disorder
Rolls, E. T., Loh, M., & Deco, G. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06379.x · Cited by 92
“This decreased depth in the basins of attraction in schizophrenia is attributed inter alia to decreased currents in N-methyld-aspartate (NMDA) receptor-activated channels (Coyle, 2006), and”
BackgroundRogasch, N. C., Daskalakis, Z. J., & Fitzgerald, P. B. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt078 · Cited by 87
Föcking, M., Dicker, P., English, J. A., Schubert, K. O., Dunn, M. J., & Cotter, D. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.43 · Cited by 90
One-carbon metabolism and schizophrenia: current challenges and future directions
Krebs, M., Bellon, A., Mainguy, G., Jay, T. M., & Frieling, H. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.10.001 · Cited by 92
Neurobiological studies on the relationship between toxoplasmosis and neuropsychiatric diseases
Fabiani, S., Pinto, B., Bonuccelli, U., & Bruschi, F. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.02.028 · Cited by 97
“As a result of the inhibitory activity exerted by KYNA on NMDA or α7nAch receptors, a reduction in glutamatergic and nicotinergic neurotransmission can be observed, which is believed to play a role in the cognitive and sensory impairment of the disease [48,49].”
BackgroundSnigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J. C., & Meltzer, H. Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156349 · Cited by 90
“Hypoglutamatergic function, particularly in the frontal cortex, has also been suggested to be a major factor in the cognitive impairment of schizophrenia (Coyle, 2006).”
BackgroundHoriguchi, M., & Meltzer, H. Y. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2561-4 · Cited by 91
“Hypoglutamatergic function in the frontal cortex and hippocampus has also been suggested to underlie the cognitive impairment in schizophrenia (Coyle 2006).”
BackgroundSpecialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders
Yuan, A., & Nixon, R. A. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.09.002 · Cited by 85
“Pharmacological and biochemical evidence supports an important role of NMDA receptor hypofunction in the pathophysiology of schizophrenia [11, 44].”
Major diencephalic inputs to the hippocampus
Vertes, R. P. (2015) · Progress in Brain Research · doi:10.1016/bs.pbr.2015.03.008 · Cited by 82
“…et al., 2010; Zhang et al., 2012a,b) provided evidence that RE is a critical component of a complex circuitry which may contribute to schizophrenia—or a circuitry that is central to the glutamate/NMDA receptor (NMDAR) hypofunction model of schizophrenia (Coyle, 1996, 2006; Javitt and Zukin, 1991).”
BackgroundKristiansen, L. V., Patel, S. A., Haroutunian, V., & Meador‐Woodruff, J. H. (2010) · Synapse · doi:10.1002/syn.20754 · Cited by 86
Allosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks
Menniti, F. S., Lindsley, C. W., Conn, P. J., Pandit, J., Zagouras, P., & Volkmann, R. A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313010005 · Cited by 99
Jones, C. A., Brown, A. M., Auer, D. P., & Fone, K. C. F. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1931-7 · Cited by 97
“While a substantial body of indirect evidence suggests that dopamine dysfunction contributes to the positive symptoms, hypofunction of prefrontal glutamate neurotransmission may contribute to the cognitive impairment seen in schizophrenia (Coyle 2006; Olney and Farber 1995).”
Dopamine transporter mutant animals: a translational perspective
Efimova, E. V., Gainetdinov, R. R., Budygin, E. A., & Sotnikova, T. D. (2016) · Journal of Neurogenetics · doi:10.3109/01677063.2016.1144751 · Cited by 94
“Another theory suggests that hypofunction of glutamate NMDA receptors is an underlying cause of schizophrenia (Mohn et al. 1999, Harrison and Weinberger 2005, Coyle 2006).”
BackgroundDifferent oxysterols have opposing actions at N-methyl-d-aspartate receptors
Linsenbardt, A. J., Taylor, A., Emnett, C. M., Doherty, J. J., Krishnan, K., Covey, D. F., Paul, S. M., Zorumski, C. F., & Mennerick, S. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.027 · Cited by 86
“Synthetic analogues of 24(S)-HC, like SGE201, have potential as treatments for schizophrenia and autism (Collingridge et al., 2013; Coyle, 2006), among other neuropsychiatric disorders.”
BackgroundTesting the glutamate hypothesis of schizophrenia
Gordon, J. A. (2009) · Nature Neuroscience · doi:10.1038/nn0110-2 · Cited by 98
Iltis, I., Koski, D. M., Eberly, L. E., Nelson, C. D., Deelchand, D. K., Valette, J., Ugurbil, K., Lim, K. O., & Henry, P. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1385 · Cited by 83
“A major hypothesis for the pathophysiology of schizophrenia is that NMDA receptor hypofunction and therefore glutamatergic dysfunction are primary events leading to hyperdopaminergia (5,16,38).”
Mismatch negativity (MMN) deficiency: A break-through biomarker in predicting psychosis onset
Näätänen, R., Shiga, T., Asano, S., & Yabe, H. (2015) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2014.12.012 · Cited by 87
Xi, D., Zhang, W., Wang, H.-X., Stradtman, G. G., & Gao, W.-J. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570900042x · Cited by 83
“Although the mechanisms underlying schizophrenia are not clear, recent advances have indicated that N-methyl-D-aspartic acid receptors (NMDARs) may play a critical role in the pathogenesis of this devastating disorder (Conn et al. 2008 ; Coyle, 2006 ; Dracheva et al. 2001; Javitt, 2004 ; Lisman et al. 2008 ; Moghaddam…”
InfluentialZheng, H.-F., Wang, W.-Q., Li, X.-M., Rauw, G., & Baker, G. B. (2017) · Amino Acids · doi:10.1007/s00726-016-2332-y · Cited by 82
“, schizophrenia and mood disorders) that have symptoms, such as cognitive impairment and problems with social interactions, in common with ASD (Coyle 2006; Grant et al. 2006; Lam et al. 2006; Labrie et al. 2008; Ongür et al. 2008; Yüksel and Öngür 2010; Durrant and Heresco-Levy 2014).”
BackgroundUnschuld, P. G., Buchholz, A. S., Varvaris, M., van Zijl, P. C. M., Ross, C. A., Pekar, J. J., Hock, C., Sweeney, J. A., Tamminga, C. A., Keshavan, M. S., et al. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt077 · Cited by 81
“These brain regions included (1) left DLPFC (Brodmann area [BA] 46, MNI −46/36/16), (2) MPFC (BA 32, MNI −4/54/−8), (3) dACC (BA 24/32, MNI −9/28/20), and (4) striate visual cortex (BA 17, MNI −13/−89/2).”
Black, M. D., Varty, G. B., Arad, M., Barak, S., Levie, A. D., Boulay, D., Pichat, P., Griebel, G., & Weiner, I. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1289-2 · Cited by 89
Sánchez, P., Peña, J., Bengoetxea, E., Ojeda, N., Elizagárate, E., Ezcurra, J., & Gutiérrez, M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt057 · Cited by 74
Zhou, L. Q., Pu, W., Wang, J., Liu, H., Wu, G., Liu, C., Mwansisya, T. E., Tao, H., Chen, X., Huang, X., et al. (2016) · Scientific Reports · doi:10.1038/srep21657 · Cited by 83
The glycine transport inhibitor sarcosine is an NMDA receptor co‐agonist that differs from glycine
Zhang, H. X., Hyrc, K. L., & Thio, L. L. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2009.168757 · Cited by 82
“According to one hypothesis, hypofunction of the NMDA receptor (NMDAR) class of glutamate receptors contributes to schizophrenia (Coyle, 2006).”
BackgroundThe role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia
Rotaru, D. C., Lewis, D. A., & Gonzalez-Burgos, G. (2012) · Reviews in the Neurosciences · doi:10.1515/revneuro-2011-0059 · Cited by 80
“5 , 249 – 275. Javitt, D.C. and Zukin, S.R. (1991). Recent advances in the phencyclidine model of schizophrenia.”
Barkus, C., Feyder, M., Graybeal, C., Wright, T., Wiedholz, L., Izquierdo, A., Kiselycznyk, C., Schmitt, W., Sanderson, D. J., Rawlins, J. N. P., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.06.005 · Cited by 82
“L-glutamate is the major excitatory neurotransmitter in the brain, and glutamatergic dysfunction is strongly implicated in neuropsychiatric diseases including anxiety, depression, bipolar disorder, and schizophrenia (Coyle, 2006).”
BackgroundDoes gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?
Fitzgerald, P. J., Barkus, C., Feyder, M., Wiedholz, L. M., Chen, Y.-C., Karlsson, R.-M., Machado-Vieira, R., Graybeal, C., Sharp, T., Zarate, C., et al. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.005 · Cited by 80
“Glutamatergic dysfunction is strongly implicated in schizophrenia and mood disorders (Coyle, 2006).”
Roffman, J. L., Brohawn, D. G., Nitenson, A. Z., Macklin, E. A., Smoller, J. W., & GOFF, D. C. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr150 · Cited by 83
“NAA is a marker of neuronal integrity for which hippocampal and prefrontal levels are consistently reduced in magnetic resonance spectroscopy studies of schizophrenia,(26,27) while glutamatergic dysfunction in schizophrenia is well established.(28) FOLH1 therefore could represent an important target in schizophrenia p…”
BackgroundAnticevic, A., Cole, M. W., Repovs, G., Savic, A., Driesen, N. R., Yang, G., Cho, Y. T., Murray, J. D., Glahn, D. C., Wang, X.-J., et al. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00169 · Cited by 78
“It is increasingly acknowledged that schizophrenia is associated with disturbances in multiple neurotransmitter systems, including alterations at the cortical microcircuit level in glutamate and γ-aminobutyric acid (GABA), as well as disturbances in dopaminergic neurotransmission along striatal-thalamic-cortical pathw…”
BackgroundRolls, E. T. (2010) · WIREs Cognitive Science · doi:10.1002/wcs.1 · Cited by 65
The genie in the bottle-magnified calcium signaling in dorsolateral prefrontal cortex
Arnsten, A. F. T., Datta, D., & Wang, M. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00973-3 · Cited by 82
Greenwood, T. A., Lazzeroni, L. C., Calkins, M. E., Freedman, R., Green, M. F., Gur, R. E., Gur, R. C., Light, G. A., Nuechterlein, K. H., Olincy, A., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.008 · Cited by 75
“Collectively, these results support a strong role for genes involved in glutamate signaling in mediating schizophrenia susceptibility, consistent with the glutamate hypothesis (Coyle, 2006; Sodhi et al., 2008).”
Thomsen, M. S., Christensen, D. Z., Hansen, H. H., Redrobe, J. P., & Mikkelsen, J. D. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.02.003 · Cited by 82
Kirkpatrick, M. P., Clarke, C. D., Sonmezturk, H. H., & Abou-Khalil, B. W. (2010) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2010.11.020 · Cited by 79
“It is mostly hypoactivity of these receptors that is known to produce symptoms of psychosis [9,10].”
Duarte, J. M. N., & Xin, L. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2521-z · Cited by 81
“Moreover, as expertly reviewed by others [2, 3, 93], astrocytes regulate the synaptic availability of NMDA receptor modulators: (1) kynurenic acid, an antagonist at the glycine binding site of the NMDA receptor, is produced from tryptophan and released by astrocytes; (2) astrocytes possess the glycine transporter type…”
Metadata
- Authors
- Coyle, J. T.
- Affiliations
- Harvard University (US)
- Corresponding author
- Coyle, Joseph T.
- ORCID
- Coyle, Joseph T.
- Venue
- Cellular and Molecular Neurobiology
- Published
- 2006-06-14
- Volume
- 26
- Issue
- 4-6
- Pages
- 363-382
- ISSN
- 0272-4340 (ISSN-L)
- 1573-6830
- PMC
- PMC11881825
- OpenAlex
- W2008639041
- Cited by
- 917
- References
- 159
- Citations by year
- 2026: 13 · 2025: 27 · 2024: 16 · 2023: 29 · 2022: 29 · 2021: 28 · 2020: 35 · 2019: 47 · 2018: 43 · 2017: 44 · 2016: 45 · 2015: 56 · 2014: 47 · 2013: 74 · 2012: 62
- FWCI
- 7.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cellular and Molecular Neurobiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (P50MH060450, MH P50-60450, MH R01-572901)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- schizophrenia, glutamate, NMDA receptor, dopamine hypothesis, negative symptoms, cognitive impairment, NMDA receptor antagonists, schizophrenia risk genes, GABAergic interneurons, antipsychotic drugs, glutamatergic neurotransmission
- MeSH terms
- Animals, Dopamine, Glutamates, Humans, Models, Biological, Synaptic Transmission, Schizophrenia, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.